ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Saikat Chowdhury
Matched on ORCID iD 0000-0002-0783-3959; OpenAlex author ID A5023247552. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 5
- IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. Co-author DOI 10.1038/s41598-026-42259-8↗
- Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. First author DOI 10.1093/oncolo/oyag423↗
- KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
- Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
- Structural and logical analysis of a comprehensive hedgehog signaling pathway to identify alternative drug targets for glioma, colon and pancreatic cancer. Co-author DOI 10.1371/journal.pone.0069132↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael James Overman · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Matthew H. G. Katz · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Abdelrahman M.G. Yousef · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Jason A. Willis · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Robert A. Wolff · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Mahmoud Yousef · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Rebecca Anne Snyder · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Anirban Maitra · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Brandon George Smaglo · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Shubham Pant · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Naruhiko Ikoma · 2 shared papers, 2025–2026 · strength 0.36
- Haoqiang Ying · 2 shared papers, 2025–2026 · strength 0.36
- Ethan Bernard Ludmir · 2 shared papers, 2025–2026 · strength 0.36
- Eugene Jon Koay · 2 shared papers, 2025–2026 · strength 0.36
- Ryan W. Huey · 2 shared papers, 2025–2026 · strength 0.36
- Dan Zhao · 2 shared papers, 2024–2025 · strength 0.32
- Akash R. Boda · 1 shared paper, 2026 · strength 0.27
- Manisha Singh · 1 shared paper, 2026 · strength 0.27
- Jason Roszik · 1 shared paper, 2026 · strength 0.27
- Scott Kopetz · 1 shared paper, 2026 · strength 0.27
- Michael A. Curran · 1 shared paper, 2026 · strength 0.27
- Ahmed Elhariri · 1 shared paper, 2026 · strength 0.19
- Dan Zhao · 1 shared paper, 2026 · strength 0.19
- Huamin Wang · 1 shared paper, 2026 · strength 0.19
- Michael P. Kim · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.